UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 729

Sortiert nach

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

Nature communications, 2021-11, Vol.12 (1), p.6436-20, Article 6436

2021

Link zum Volltext

Verfügbarkeit prüfen

RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)

PLoS genetics, 2022-10, Vol.18 (10), p.e1010300-e1010300

2022

Link zum Volltext

Verfügbarkeit prüfen

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

PloS one, 2016-08, Vol.11 (8), p.e0161470

2016

Link zum Volltext

Verfügbarkeit prüfen

Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia

International journal of molecular sciences, 2022-04, Vol.23 (9), p.4574

2022

Link zum Volltext

Verfügbarkeit prüfen

Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression

Frontiers in oncology, 2023-07, Vol.13, p.1177871-1177871

2023

Link zum Volltext

Verfügbarkeit prüfen

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Blood, 2007-12, Vol.110 (12), p.4064-4072

2007

Link zum Volltext

Verfügbarkeit prüfen

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

Scientific reports, 2023-08, Vol.13 (1), p.13110-13110, Article 13110

2023

Link zum Volltext

Verfügbarkeit prüfen

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2761-2767

2010

Link zum Volltext

Verfügbarkeit prüfen

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

PloS one, 2018-01, Vol.13 (1), p.e0192180

2018

Link zum Volltext

Verfügbarkeit prüfen

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3553

2023

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

Clinical cancer research, 2008-06, Vol.14 (12), p.3881-3888

2008

Link zum Volltext

Verfügbarkeit prüfen

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Haematologica (Roma), 2018-12, Vol.103 (12), p.2026-2032

2018

Link zum Volltext

Verfügbarkeit prüfen

DUX Hunting—Clinical Features and Diagnostic Challenges Associated with DUX4-Rearranged Leukaemia

Cancers, 2020-10, Vol.12 (10), p.2815

2020

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis

Frontiers in oncology, 2022-04, Vol.12, p.851572

2022

Link zum Volltext

Verfügbarkeit prüfen

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

Frontiers in cell and developmental biology, 2022-07, Vol.10, p.942053-942053

2022

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten

Epigenetics & chromatin, 2018-05, Vol.11 (1), p.24-24, Article 24

2018

Link zum Volltext

Verfügbarkeit prüfen

Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients

Cancers, 2023-09, Vol.15 (19), p.4731

2023

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A -Rearranged Acute Lymphoblastic Leukemia

Genes, 2023-01, Vol.14 (2), p.264

2023

Link zum Volltext

Verfügbarkeit prüfen

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

NPJ precision oncology, 2021-08, Vol.5 (1), p.1-13, Article 75

2021

Link zum Volltext

Verfügbarkeit prüfen

Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients

Cancers, 2020-12, Vol.12 (12), p.3738

2020

Link zum Volltext

Verfügbarkeit prüfen

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Haematologica (Roma), 2012-06, Vol.97 (6), p.907-914

2012

Link zum Volltext

Verfügbarkeit prüfen

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

Blood, 2017-03, Vol.129 (9), p.1166-1176

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 729

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(660)
Mit Volltextzugriff
(659)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(728)
Japanisch
(79)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia

Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

DUX Hunting—Clinical Features and Diagnostic Challenges Associated with DUX4-Rearranged Leukaemia

Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten

Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients

Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A -Rearranged Acute Lymphoblastic Leukemia

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

Suchergebnisse filtern